deucravacitinib
Sponsor Bristol Myers Squibb CO · listed as BMY
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
Next catalyst
Event typeREADOUT
Expected date2026-07-25
As disclosedJul 25, 2026
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT04036435
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorBristol-Myers Squibb
Listed asBMY
Condition(s)Psoriasis
All tracked catalysts for deucravacitinib
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2026-07-25 | READOUT | medium | NCT04036435 |
| 2026-10-19 | READOUT | medium | NCT05617677 |
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More BMY catalysts